Cognitive dysfunction in major depression and bipolar disorder: Assessment and treatment options

Psychiatry and Clinical Neurosciences

Volumn 71, Issue 1, 2017, Pages 18-27

  MacQueen, Glenda M ^a   Memedovich, Katherine A ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

bipolar; cognition; major depressive disorder; neuropsychological; treatment

Indexed keywords

ATOMOXETINE; DOCOSAHEXAENOIC ACID; GALANTAMINE; INSULIN; LITHIUM; MODAFINIL; VITAMIN D; VORTIOXETINE;

ATTENTION DEFICIT DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLOCK DRAWING TEST; COGNITION; COGNITIVE DEFECT; COGNITIVE REHABILITATION; COGNITIVE REMEDIATION THERAPY; COMORBIDITY; DEMENTIA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ELECTROCONVULSIVE THERAPY; EMOTION; EXECUTIVE FUNCTION; EXERCISE; HUMAN; LONGITUDINAL STUDY; MAJOR DEPRESSION; META ANALYSIS (TOPIC); MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; ONSET AGE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION; REVIEW; SELF REPORT; SOCIAL COGNITION; WECHSLER MEMORY SCALE; BIPOLAR DISORDER; COGNITIVE DYSFUNCTION; COMPLICATION;

BIPOLAR DISORDER; COGNITIVE DYSFUNCTION; DEPRESSIVE DISORDER, MAJOR; HUMANS;

EID: 85006043642     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12463     Document Type: Review

References (91)

1. Bora E, Yucel M, Pantelis C. Cognitive impairment in affective psychoses: A meta-analysis. Schizophr. Bull. 2010; 36: 112–125.
2. Hill SK, Reilly JL, Harris MS et al. A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia. Schizophr. Res. 2009; 113: 167–175.
3. Paradiso S, Lamberty GJ, Garvey MJ, Robinson RG. Cognitive impairment in the euthymic phase of chronic unipolar depression. J. Nerv. Ment. Dis. 1997; 185: 748–754.
4. Xu G, Lin K, Rao D et al. Neuropsychological performance in bipolar I, bipolar II and unipolar depression patients: A longitudinal, naturalistic study. J. Affect. Disord. 2012; 136: 328–339.
5. Daniel BD, Montali A, Gerra ML et al. Cognitive impairment and its associations with the path of illness in affective disorders: A comparison between patients with bipolar and unipolar depression in remission. J. Psychiatr. Pract. 2013; 19: 275–287.
6. Gruber S, Rathgeber K, Braunig P, Gauggel S. Stability and course of neuropsychological deficits in manic and depressed bipolar patients compared to patients with major depression. J. Affect. Disord. 2007; 104: 61–71.
7. Stoddart SD, Craddock NJ, Jones LA. Differentiation of executive and attention impairments in affective illness. Psychol. Med. 2007; 37: 1613–1623.
8. Smith YR, Love T, Persad CC, Tkaczyk A, Nichols TE, Zubieta JK. Impact of combined estradiol and norethindrone therapy on visuospatial working memory assessed by functional magnetic resonance imaging. J. Clin. Endocrinol. Metab. 2006; 91: 4476–4481.
9. Cotrena C, Branco LD, Shansis FM, Fonseca RP. Executive function impairments in depression and bipolar disorder: Association with functional impairment and quality of life. J. Affect. Disord. 2016; 190: 744–753.
10. Cullen B, Nicholl BI, Mackay DF et al. Cognitive function and lifetime features of depression and bipolar disorder in a large population sample: Cross-sectional study of 143,828 UK Biobank participants. Eur. Psychiatry 2015; 30: 950–958.
11. Miskowiak K, Vinberg M, Christensen EM, Kessing LV. Is there a difference in subjective experience of cognitive function in patients with unipolar disorder versus bipolar disorder? Nord. J. Psychiatry 2012; 66: 389–395.
12. El Hammi E, Samp J, Remuzat C et al. Difference of perceptions and evaluation of cognitive dysfunction in major depressive disorder patients across psychiatrists internationally. Ther. Adv. Psychopharmacol. 2014; 4: 22–29.
13. Lim J, Oh IK, Han C et al. Sensitivity of cognitive tests in four cognitive domains in discriminating MDD patients from healthy controls: A meta-analysis. Int. Psychogeriatr. 2013; 25: 1543–1557.
14. Bakkour N, Samp J, Akhras K et al. Systematic review of appropriate cognitive assessment instruments used in clinical trials of schizophrenia, major depressive disorder and bipolar disorder. Psychiatry Res. 2014; 216: 291–302.
15. Keefe RS, Fox KH, Davis VG et al. The Brief Assessment of Cognition in Affective Disorders (BAC-A): Performance of patients with bipolar depression and healthy controls. J. Affect. Disord. 2014; 166: 86–92.
16. Peters AT, Peckham AD, Stange JP et al. Correlates of real world executive dysfunction in bipolar I disorder. J. Psychiatr. Res. 2014; 53: 87–93.
17. Bonnín Cdel M, Gonzalez-Pinto A, Solé B et al. Verbal memory as a mediator in the relationship between subthreshold depressive symptoms and functional outcome in bipolar disorder. J. Affect. Disord. 2014; 160: 50–54.
18. Lee RS, Hermens DF, Naismith SL et al. Neuropsychological and functional outcomes in recent-onset major depression, bipolar disorder and schizophrenia-spectrum disorders: A longitudinal cohort study. Transl. Psychiatry 2015; 5: e555.
19. Bowie CR, Depp C, McGrath JA et al. Prediction of real-world functional disability in chronic mental disorders: A comparison of schizophrenia and bipolar disorder. Am. J. Psychiatry 2010; 167: 1116–1124.
20. Cusi AM, Nazarov A, Macqueen GM, McKinnon MC. Theory of mind deficits in patients with mild symptoms of major depressive disorder. Psychiatry Res. 2013; 210: 672–674.
21. Cusi A, Macqueen GM, McKinnon MC. Altered self-report of empathic responding in patients with bipolar disorder. Psychiatry Res. 2010; 178: 354–358.
22. Cusi AM, Nazarov A, Holshausen K, Macqueen GM, McKinnon MC. Systematic review of the neural basis of social cognition in patients with mood disorders. J. Psychiatry Neurosci. 2012; 37: 154–169.
23. Lee RS, Hermens DF, Porter MA, Redoblado-Hodge MA. A meta-analysis of cognitive deficits in first-episode major depressive disorder. J. Affect. Disord. 2012; 140: 113–124.
24. Trivedi MH, Greer TL. Cognitive dysfunction in unipolar depression: Implications for treatment. J. Affect. Disord. 2014; 152–154: 19–27.
25. Torres IJ, Kozicky J, Popuri S et al. 12-month longitudinal cognitive functioning in patients recently diagnosed with bipolar disorder. Bipolar Disord. 2014; 16: 159–171.
26. Frias A, Palma C, Farriols N. Neurocognitive impairments among youth with pediatric bipolar disorder: A systematic review of neuropsychological research. J. Affect. Disord. 2014; 166: 297–306.
27. Bora E, Harrison BJ, Yucel M, Pantelis C. Cognitive impairment in euthymic major depressive disorder: A meta-analysis. Psychol. Med. 2013; 43: 2017–2026.
28. Truong W, Minuzzi L, Soares CN et al. Changes in cortical thickness across the lifespan in major depressive disorder. Psychiatry Res. 2013; 214: 204–211.
29. Kurtz MM, Gerraty RT. A meta-analytic investigation of neurocognitive deficits in bipolar illness: Profile and effects of clinical state. Neuropsychology 2009; 23: 551–562.
30. Robinson LJ, Thompson JM, Gallagher P et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J. Affect. Disord. 2006; 93: 105–115.
31. Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: A meta-analysis. Acta Psychiatr. Scand. Suppl. 2007; 434: 17–26.
32. Arts B, Jabben N, Krabbendam L, van Os J. Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives. Psychol. Med. 2008; 38: 771–785.
33. Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: A meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J. Affect. Disord. 2009; 113: 1–20.
34. Mann-Wrobel MC, Carreno JT, Dickinson D. Meta-analysis of neuropsychological functioning in euthymic bipolar disorder: An update and investigation of moderator variables. Bipolar Disord. 2011; 13: 334–342.
35. Douglas KM, Porter RJ. Longitudinal assessment of neuropsychological function in major depression. Aust. N. Z. J. Psychiatry 2009; 43: 1105–1117.
36. Volkert J, Schiele MA, Kazmaier J et al. Cognitive deficits in bipolar disorder: From acute episode to remission. Eur. Arch. Psychiatry Clin. Neurosci. 2016; 266: 225–237.
37. MacQueen GM, Galway TM, Hay J, Young LT, Joffe RT. Recollection memory deficits in patients with major depressive disorder predicted by past depressions but not current mood state or treatment status. Psychol. Med. 2002; 32: 251–258.
38. King MJ, MacDougall AG, Ferris SM, Levine B, MacQueen GM, McKinnon MC. A review of factors that moderate autobiographical memory performance in patients with major depressive disorder. J. Clin. Exp. Neuropsychol. 2010; 32: 1122–1144.
39. Fleming SK, Blasey C, Schatzberg AF. Neuropsychological correlates of psychotic features in major depressive disorders: A review and meta-analysis. J. Psychiatr. Res. 2004; 38: 27–35.
40. Bora E, Yucel M, Pantelis C. Neurocognitive markers of psychosis in bipolar disorder: A meta-analytic study. J. Affect. Disord. 2010; 127: 1–9.
41. Gorwood P, Corruble E, Falissard B, Goodwin GM. Toxic effects of depression on brain function: Impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am. J. Psychiatry 2008; 165: 731–739.
42. Samame C, Martino DJ, Strejilevich SA. Longitudinal course of cognitive deficits in bipolar disorder: A meta-analytic study. J. Affect. Disord. 2014; 164: 130–138.
43. Martino DJ, Strejilevich SA, Marengo E et al. Relationship between neurocognitive functioning and episode recurrences in bipolar disorder. J. Affect. Disord. 2013; 147: 345–351.
44. Godard J, Baruch P, Grondin S, Lafleur MF. Psychosocial and neurocognitive functioning in unipolar and bipolar depression: A 12-month prospective study. Psychiatry Res. 2012; 196: 145–153.
45. Kozicky JM, Torres IJ, Silveira LE, Bond DJ, Lam RW, Yatham LN. Cognitive change in the year after a first manic episode: Association between clinical outcome and cognitive performance early in the course of bipolar I disorder. J. Clin. Psychiatry 2014; 75: e587–e593.
46. Lera-Miguel S, Andres-Perpina S, Fatjo-Vilas M, Fananas L, Lazaro L. Two-year follow-up of treated adolescents with early-onset bipolar disorder: Changes in neurocognition. J. Affect. Disord. 2014; 172C: 48–54.
47. Cusi AM, Macqueen GM, McKinnon MC. Patients with bipolar disorder show impaired performance on complex tests of social cognition. Psychiatry Res. 2012; 200: 258–264.
48. Jaworska N, Yang XR, Knott V, Macqueen G. A review of fMRI studies during visual emotive processing in major depressive disorder. World J. Biol. Psychiatry 2014; 16: 448–471.
49. Bourne C, Aydemir O, Balanza-Martinez V et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: An individual patient data meta-analysis. Acta Psychiatr. Scand. 2013; 128: 149–162.
50. Solé B, Jimenez E, Martinez-Aran A, Vieta E. Cognition as a target in major depression: New developments. Eur. Neuropsychopharmacol. 2015; 25: 231–247.
51. Connolly KR, Thase ME. Vortioxetine: A new treatment for major depressive disorder. Expert Opin. Pharmacother. 2016; 17: 421–431.
52. Wagner S, Doering B, Helmreich I, Lieb K, Tadic A. A meta-analysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepressant treatment. Acta Psychiatr. Scand. 2012; 125: 281–292.
53. Keefe RS, McClintock SM, Roth RM, Doraiswamy PM, Tiger S, Madhoo M. Cognitive effects of pharmacotherapy for major depressive disorder: A systematic review. J. Clin. Psychiatry 2014; 75: 864–876.
54. Snyder HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: A meta-analysis and review. Psychol. Bull. 2013; 139: 81–132.
55. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int. J. Neuropsychopharmacol. 2014; 17: 1557–1567.
56. Wingo AP, Wingo TS, Harvey PD, Baldessarini RJ. Effects of lithium on cognitive performance: A meta-analysis. J. Clin. Psychiatry 2009; 70: 1588–1597.
57. Pfennig A, Alda M, Young T et al. Prophylactic lithium treatment and cognitive performance in patients with a long history of bipolar illness: No simple answers in complex disease-treatment interplay. Int. J. Bipolar Disord. 2014; 2: 1.
58. Dias VV, Balanza-Martinez V, Soeiro-de-Souza MG et al. Pharmacological approaches in bipolar disorders and the impact on cognition: A critical overview. Acta Psychiatr. Scand. 2012; 126: 315–331.
59. Goldberg JF, Chengappa KN. Identifying and treating cognitive impairment in bipolar disorder. Bipolar Disord. 2009; 11 (Suppl. 2): 123–137.
60. Howland RH. The use of dopaminergic and stimulant drugs for the treatment of depression. J. Psychosoc. Nurs. Ment. Health Serv. 2012; 50: 11–14.
61. Michelson D, Adler LA, Amsterdam JD et al. Addition of atomoxetine for depression incompletely responsive to sertraline: A randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2007; 68: 582–587.
62. Bond DJ, Hadjipavlou G, Lam RW et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann. Clin. Psychiatry 2012; 24: 23–37.
63. Fava M, Thase ME, DeBattista C, Doghramji K, Arora S, Hughes RJ. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann. Clin. Psychiatry 2007; 19: 153–159.
64. Frye MA, Grunze H, Suppes T et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am. J. Psychiatry 2007; 164: 1242–1249.
65. Cummings JL. Cholinesterase inhibitors: A new class of psychotropic compounds. Am. J. Psychiatry 2000; 157: 4–15.
66. Elgamal S, MacQueen G. Galantamine as an adjunctive treatment in major depression. J. Clin. Psychopharmacol. 2008; 28: 357–359.
67. Matthews JD, Siefert CJ, Blais MA et al. A double-blind, placebo-controlled study of the impact of galantamine on anterograde memory impairment during electroconvulsive therapy. J. ECT 2013; 29: 170–178.
68. McIntyre RS, Soczynska JK, Woldeyohannes HO et al. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disord. 2012; 14: 697–706.
69. Jaeggi SM, Buschkuehl M, Jonides J, Perrig WJ. Improving fluid intelligence with training on working memory. Proc. Natl. Acad. Sci. U. S. A. 2008; 105: 6829–6833.
70. Anaya C, Martinez Aran A, Ayuso-Mateos JL, Wykes T, Vieta E, Scott J. A systematic review of cognitive remediation for schizo-affective and affective disorders. J. Affect. Disord. 2012; 142: 13–21.
71. Motter JN, Pimontel MA, Rindskopf D, Devanand DP, Doraiswamy PM, Sneed JR. Computerized cognitive training and functional recovery in major depressive disorder: A meta-analysis. J. Affect. Disord. 2016; 189: 184–191.
72. Meusel LA, Hall GB, Fougere P, McKinnon MC, MacQueen GM. Neural correlates of cognitive remediation in patients with mood disorders. Psychiatry Res. 2013; 214: 142–152.
73. Deckersbach T, Nierenberg AA, Kessler R et al. RESEARCH: Cognitive rehabilitation for bipolar disorder: An open trial for employed patients with residual depressive symptoms. CNS Neurosci. Ther. 2010; 16: 298–307.
74. Naismith SL, Redoblado-Hodge MA, Lewis SJ, Scott EM, Hickie IB. Cognitive training in affective disorders improves memory: A preliminary study using the NEAR approach. J. Affect. Disord. 2010; 121: 258–262.
75. Demant KM, Almer GM, Vinberg M, Kessing LV, Miskowiak KW. Effects of cognitive remediation on cognitive dysfunction in partially or fully remitted patients with bipolar disorder: Study protocol for a randomized controlled trial. Trials 2013; 14: 378.
76. van Praag H, Shubert T, Zhao C, Gage FH. Exercise enhances learning and hippocampal neurogenesis in aged mice. J. Neurosci. 2005; 25: 8680–8685.
77. Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: Key roles of growth factor cascades and inflammation. Trends Neurosci. 2007; 30: 464–472.
78. Vasques PE, Moraes H, Silveira H, Deslandes AC, Laks J. Acute exercise improves cognition in the depressed elderly: The effect of dual-tasks. Clinics (Sao Paulo) 2011; 66: 1553–1557.
79. Kubesch S, Bretschneider V, Freudenmann R et al. Aerobic endurance exercise improves executive functions in depressed patients. J. Clin. Psychiatry 2003; 64: 1005–1012.
80. Hoffman BM, Blumenthal JA, Babyak MA et al. Exercise fails to improve neurocognition in depressed middle-aged and older adults. Med. Sci. Sports Exerc. 2008; 40: 1344–1352.
81. Greer TL, Grannemann BD, Chansard M, Karim AI, Trivedi MH. Dose-dependent changes in cognitive function with exercise augmentation for major depression: Results from the TREAD study. Eur. Neuropsychopharmacol. 2014; 25: 248–256.
82. Strassnig MT, Signorile JF, Potiaumpai M et al. High velocity circuit resistance training improves cognition, psychiatric symptoms and neuromuscular performance in overweight outpatients with severe mental illness. Psychiatry Res. 2015; 229: 295–301.
83. Buford TW, Roberts MD, Church TS. Toward exercise as personalized medicine. Sports Med. 2013; 43: 157–165.
84. Luchtman DW, Song C. Cognitive enhancement by omega-3 fatty acids from child-hood to old age: Findings from animal and clinical studies. Neuropharmacology 2013; 64: 550–565.
85. Karr JE, Alexander JE, Winningham RG. Omega-3 polyunsaturated fatty acids and cognition throughout the lifespan: A review. Nutr. Neurosci. 2011; 14: 216–225.
86. Turnbull T, Cullen-Drill M, Smaldone A. Efficacy of omega-3 fatty acid supplementation on improvement of bipolar symptoms: A systematic review. Arch. Psychiatr. Nurs. 2008; 22: 305–311.
87. Antypa N, Smelt AH, Strengholt A, Van der Does AJ. Effects of omega-3 fatty acid supplementation on mood and emotional information processing in recovered depressed individuals. J. Psychopharmacol. 2012; 26: 738–743.
88. Rogers PJ, Appleton KM, Kessler D et al. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: A randomised controlled trial. Br. J. Nutr. 2008; 99: 421–431.
89. Li G, Mbuagbaw L, Samaan Z et al. Efficacy of vitamin D supplementation in depression in adults: A systematic review. J. Clin. Endocrinol. Metab. 2014; 99: 757–567.
90. Khoraminya N, Tehrani-Doost M, Jazayeri S, Hosseini A, Djazayery A. Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder. Aust. N. Z. J. Psychiatry 2013; 47: 271–275.
91. Nadeau SE, Bowers D, Jones TL, Wu SS, Triggs WJ, Heilman KM. Cognitive effects of treatment of depression with repetitive transcranial magnetic stimulation. Cogn. Behav. Neurol. 2014; 27: 77–87.